The effects of organizational status on market entry timing and performance: The biopharmaceutical industry amid environmental disruption
研究发现在环境动荡（如疫情）中，中等地位的生物制药企业比高地位或低地位企业更快进入新市场，但后续财务绩效却更低。
While scholars debate the risk-taking behaviors of middle-status organizations, little is known about their boundary conditions and performance outcomes. Our research addresses this gap by examining how a firm’s organizational status in the scientific knowledge community influences its market-entry decisions during environmental turbulence. Using a unique dataset of the global biopharmaceutical industry during the recent pandemic, we reveal that middle-status firms entered the new market faster than either low- or high-status firms. Additionally, firms’ prior market-entry failures and the new market’s uncertainty amplified the relationship between firm status and market-entry speed. Despite their rapid market entry and subsequent superior innovation performance, middle-status firms had lower post-entry financial performance than high- or low-status firms. By examining the interplay between organizational status, market entry timing, and performance, we offer valuable insights for firms seeking to grow in rapidly evolving contexts, highlighting the role of firm status during environmental turbulence.